NVSNovartis PharmaceuticalsRunning, no new patients
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
B-Cell Acute Lymphoblastic Leukemia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 121 (final count)
- Started
- Jun 24, 2019
- Main results expected
- Oct 19, 2027
- Fully finished
- Oct 19, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Disease Free Survival (DFS) rate without censoring for new anticancer therapy, including Stem Cell Transplantation (SCT) while in remission
Measured over: 5 years after tisagenlecleucel infusion
Overall Survival (OS) rate
Measured over: 4 years after tisagenlecleucel
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03876769 · record last updated 2026-08-19 · checked 2026-11-09 15:47 UTC